Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Stability of FPPs- Conducting, Bracketing, Matrixing PowerPoint Presentation
Download Presentation
Stability of FPPs- Conducting, Bracketing, Matrixing

Stability of FPPs- Conducting, Bracketing, Matrixing

204 Views Download Presentation
Download Presentation

Stability of FPPs- Conducting, Bracketing, Matrixing

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Stability of FPPs- Conducting, Bracketing, Matrixing Sultan Ghani

  2. Focus of the Presentation • Stability of Finished Pharmaceutical Product (FPP) • Bracketing & Matrixing

  3. Stability of Finished Pharmaceutical Product • Pre-formulation studies on pilot scale batch should be conducted • Stress testing may be performed on the pharmaceutical product • Selection of batches: At least two pilot scale batches and the third one can be smaller • Container closure system should be the same as proposed for marketing

  4. Stability of Finished Pharmaceutical Product • Specification: Appropriate physical, chemical, biological and microbiological attributes, also preservative content • Shelf-life acceptance criteria should be established, as well as difference between shelf-life and release specifications • A single stability batch should be tested for antimicrobial preservative effectiveness • Validated stability indicating analytical procedure should be applied

  5. Stability of Finished Pharmaceutical Product • Testing frequency: Frequency of testing should be sufficient to establish stability profile for product. For proposed shelf-life of 12 months, the frequency of testing should be three months over the first year, six months over the second year, and annually thereafter. For accelerated storage, a minimum of three time points (036) is recommended. • Reduced design: Matrixing and bracketing principle can be used if justified • Storage condition should be monitored and recorded (see Table 1)

  6. Stability of Finished Pharmaceutical Product • Commitment: Long-term stability data do not cover the proposed shelf-life granted at the time of approval. Commitment should be made to continue stability studies (post-approval). Three production batches covering the proposed shelf-life. • Evaluation: Systematic approach for the evaluation of the stability information, including all attributes. All results must remain within specification throughout the shelf-life. If the data are limited, it is unnecessary to go through the statistical analysis.

  7. Storage Condition for FPP Table 1

  8. Statement Labeling (Table 2)

  9. Q1D - Bracketing and Matrixing

  10. Q1D - Bracketing and Matrixing • Outlines recommendations, principles, and considerations for reduced designs. • Terms: • Full Design: samples for every combination of all design factors are tested at all time points • Reduced Design: not all samples for every factor combination are tested at all time points • Bracketing: testing samples on the extremes of certain design factors (e.g., strengths, container sizes and/or fills)

  11. Q1D - Bracketing and Matrixing • Terms (cont’d): • Matrixing: testing a selected subset of the total number of possible samples for all factor combinations at a specified time point, while testing another subset of samples at a subsequent time point

  12. Q1D - Bracketing and Matrixing • Basic Principles: • some reduced designs may need minimal justification, some designs may require more justification • assumptions should be assessed and justified • potential risks should be taken into consideration • Note: • if a reduced design is proposed to be implemented after approval of the original submission, a prior approval application should be filed (e.g., in Canada: a “Level 2 - Notifiable Change”)

  13. Q1D - Bracketing and Matrixing • Bracketing - Strengths: • Applicable: strengths of identical or closely related formulations • Applicable with additional justification (e.g., supporting data): strengths where the relative amounts of the drug substance and excipients vary within the product line • Not applicable: different excipients among strengths

  14. Q1D - Bracketing and Matrixing • Bracketing – Container Size, Fill: • Applicable: same container closure system where either the container size or fill varies while the other remains constant • Applicable with additional justification (e.g., supporting data): same container closure system but both the container size and fill vary • Not applicable: different container closure systems

  15. Q1D - Bracketing and Matrixing

  16. Q1D - Bracketing and Matrixing

  17. Q1D - Bracketing and Matrixing • Bracketing - Considerations: • If stability of extremes are shown to be different, the intermediates should be considered no more stable than the least stable extreme • Selected extreme may be dropped from proposed market presentations

  18. Q1D - Bracketing and Matrixing • Matrixing: • applicable: • strengths with identical or closely related formulations • container sizes or fills of the same C/C system • different batches made with the same equipment and process • applicable with additional justification: • where the relative amounts of excipients change or different excipients are used • not applicable: • different storage conditions • different test attributes

  19. Q1D - Bracketing and Matrixing • Matrixing - Considerations: • - Design should be balanced as far as possible so that each combination is tested to the same extent over the intended duration of the study and through the last time point prior to submission • - Where time points are matrixed, all selected factor combinations should be tested at the initial and final time points (and the last time point prior to submission)

  20. Q1D - Bracketing and MatrixingMATRIXING - Simple design on time points:A true, but not practical, “one-half reduction”:

  21. Q1D - Bracketing and MatrixingMATRIXING - Simple design on time points:

  22. Thank you!!!!!!!!